DIXi Group Parnters with Aleva Neurotherapeutics

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash.

Global Surgical Lasers Market to Reach $10.1 Billion by 2027

1 Billion by 2027, growing at a CAGR of 9.7% over the analysis period 2020-2027. Solid-State Laser Systems, one of the segments analyzed in the report, is projected to record a 9.2% CAGR and reach US$3.9 Billion by the end of the analysis period.

Carestream Health Advances X-ray Image Quality with Smart Noise Cancellation

SNC has received FDA 510(k) Clearance and is available as an optional feature with Carestream’s ImageView Software powered by Eclipse—the intelligent image-processing engine behind the company’s innovative imaging software—on DRX-Evolution and DRX-Evolution Plus systems.

DIXI Holding Le Locle SA and Aleva Neurotherapeutics SA have co-founded Adept Neuro SA, a Joint Venture dedicated to developing  a new generation of Stereo-Electro-Encephalo-Graphie (SEEG) electrodes which will facilitate localization and thermocoagulation of epileptogenic zones.

Aleva Neurotherapeutics, a spin-off of the Swiss Federal Institute of Technology (EPFL) Microsystems Laboratory, has developed a unique technology for the manufacture of electrodes allowing precise stimulation of the deep brain. Aleva’s electrodes are based on MEMS technology, which allows great flexibility of design and miniaturization, opening the door to new product development avenues and cost efficient industrialization of the manufacturing process.

DIXI Medical SAS in Besançon is the world leader in the manufacture of intracerebral electrodes for SEEG. The current conventional mode of production limits the company’s ability to meet the demand of a rapidly growing market and prohibits the necessary evolution in therapeutic modalities that only the nanotech dimension can facilitate.

Adept Neuro has exclusive intellectual property rights developed by Aleva Neurotherapeutics in the field of epilepsy. DIXI Holding will ensure the full financing of the joint venture and will gradually become the sole shareholder, while DIXI Medical SAS will ensure the exclusive production and distribution of products developed by Adept Neuro.

Dr André Mercanzini, CEO of Aleva Neurotherapeutics SA (Lausanne, Switzerland) explains the importance of the partnership: “Our technology has demonstrated its clinical efficacy in the most demanding applications of neurosurgery. With the long and pioneering experience of Dixi in Epilepsy, we are sure to transform the lives of patients for the better”

Mr Frédéric Koehn COO of DIXI Holding SA (Le Locle, Switzerland) stressed that this investment is a major sign of the Dixi Group’s new ambitions: “Dixi is dedicated to improving the lives of epileptic patients by providing new technologies to Neurologists and Neurosurgeons. We aim to become a major integrated player for the diagnostic and surgical treatment of Epilepsy.”

Adept Neuro SA will be based at the EPFL Innovation Park in Lausanne, Switzerland.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles